|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/133 | |
| A61K 31/135 | |||
| A61K 31/137 | |||
| A61K 31/00 | |||
| A61K 45/06 | |||
| A61P 25/28 |
| (11) | Patento numeris | 1713459 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 04804037.2 |
| Europos patento paraiškos padavimo data | 2004-12-17 | |
| (97) | Europos patento paraiškos paskelbimo data | 2006-10-25 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2010-07-21 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2004/014436 |
| Data | 2004-12-17 |
| (87) | Numeris | WO 2005/058295 |
| Data | 2005-06-30 |
| (30) | Numeris | Data | Šalis |
| 0329498 | 2003-12-19 | GB |
| (72) |
BRINKMANN, Volker, DE
KANEIDER, Nicole, AT
WIEDERMANN, Christian, J., AT
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
Novartis Pharma GmbH, Brunner Strasse 59, 1230 Wien, AT |
| (54) | USE OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONISTS FOR THE TREATMENT OF BRAIN DEGENERATIVE DISEASES |
| USE OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONISTS FOR THE TREATMENT OF BRAIN DEGENERATIVE DISEASES |